Nextera’s unique pVII phage display technology expands insights into the biology of human FSAP haemostasis

Apr 20, 2020 | Publications

In ChemBioChem we describe the employment of Nextera’s pVII peptide phage display technology in the fine-mapping of FSAP enzyme substrate specificity, which shows surprising new results. Read the paper here

Factor-VII activating protease (FSAP) is a ubiquitously circulating zymogen plasma serine protease, which is rapidly activated upon tissue injury. FSAP has diverse effects in haemostasis, and its mode of action is incompletely understood.  The study conducted in collaboration with Professor Sandip Kanses group at the Institute of Basic Medical Sciences at the University of Oslo, suggests that yet unknown in vivo FSAP substrates exist. These need to be identified to gain necessary insight into FSAP’s function in health and disease. This knowlegde may foster novel intervention in e.g. hemorrhagic and ischemic stroke. The study also validated improvement of this powerful application of Nextera’s unique platform. The platform will thus facilitate the discovery of novel specific drugs in diseases related to enzymatic pathways.